Skip to main content
Department of Health Department of Health An Roinn Sláinte Männystrie O Pouste

Main navigation

  • Home
  • Topics
  • Publications
  • Consultations
  • Contact

Translation help

Translate this page

Select a language

  • Arabic — عربي
  • Chinese (Simplified) — 中文简体
  • Chinese (Traditional) — 中文繁體
  • Dutch — Nederlands
  • Filipino — Filipino
  • French — Français
  • German — Deutsch
  • Hungarian — Magyar
  • Irish — Gaeilge
  • Italian — Italiano
  • Latvian — Latviešu
  • Lithuanian — Lietuvių kalba
  • Polish — Polski
  • Portuguese — Português
  • Romanian — Română
  • Russian — Русский
  • Slovak — Slovenčina
  • Spanish — Español
  • Ukrainian — Українська
  • NICE - Endorsed Technology Appraisals 2026/2027

    Topics:
    • DoH Statistics and Research, 
    • Safety and Quality, 
    • Safety and quality statistics, 
    • Social Care Institute for Excellence (SCIE), 
    • NICE technology appraisals

    It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.

    Technology Appraisals Endorsement Process

    The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;

    NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.

    For information, details of the previous arrangement can be found on the following circular;

    NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11

    2026/2027

    The following technology appraisals have been endorsed during 2025/26. Information on technology appraisals endorsed in previous years can be found on the homepage.

    June 2026

    TA1153 - Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment

    TA1152 - Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity

    TA1150 - Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer

    May 2026

    TA1149 - Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myeloma

    TA1148 - Sodium zirconium cyclosilicate for treating hyperkalaemia

    • Note this guidance updates and replaces NICE Technology Appraisal TA599, endorsed by the DoH in October 2019

    TA1147 - Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over

    TA1146 - Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors

    • Note this guidance updates and replaces NICE Technology Appraisal TA881, endorsed by the DoH in May 2023

    TA1145 - Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma

    April 2026

    TA1143 - Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause

    TA1142 - Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils

    TA1140 - Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over 

    • Note this guidance updates and replaces NICE Technology Appraisal TA1088, endorsed by the DoH in September 2025

    TA1139 - Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment

    Related content

    • DoH NISCC Sponsorship Officer
    • NICE - Endorsed Technology Appraisals 2006/2007
    • NICE - Endorsed Technology Appraisals 2007/2008
    • NICE - Endorsed Technology Appraisals 2008/2009
    • NICE - Endorsed Technology Appraisals 2009/2010
    • NICE - Endorsed Technology Appraisals 2010/2011
    • NICE - Endorsed Technology Appraisals 2011/2012
    • NICE - Endorsed Technology Appraisals 2012/2013
    • NICE - Endorsed Technology Appraisals 2013/2014
    • NICE - Endorsed Technology Appraisals 2014/2015
    • NICE - Endorsed Technology Appraisals 2015/2016
    • NICE - Endorsed Technology Appraisals 2016/2017
    • NICE - Endorsed Technology Appraisals 2017/2018
    • NICE - Endorsed Technology Appraisals 2018/2019
    • NICE - Endorsed Technology Appraisals 2019/2020
    • NICE - Endorsed Technology Appraisals 2020/2021
    • NICE - Endorsed Technology Appraisals 2021/2022
    • NICE - Endorsed Technology Appraisals 2022/2023
    • NICE - Endorsed Technology Appraisals 2023/2024
    • NICE - Endorsed Technology Appraisals 2024/2025
    • NICE - Endorsed Technology Appraisals 2025/2026
    • NICE Technology Appraisals
    Share this page Share on Facebook (external link opens in a new window / tab) Share on X (external link opens in a new window / tab) Share by email (external link opens in a new window / tab)

    Department footer links

    • Crown copyright
    • Terms and Conditions
    • Privacy
    • Cookies
    • Accessibility
    • The Northern Ireland Executive
    • The Executive Office
    • Department of Agriculture, Environment and Rural Affairs
    • Department for Communities
    • Department for Education
    • Department for the Economy
    • Department of Finance
    • Department for Infrastructure
    • Department for Health
    • Department of Justice
    • nidirect.gov.uk — the official government website for Northern Ireland citizens